These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23286841)

  • 21. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY; Ferrante SA; Elbasha EH; Hsu TY
    Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic strategies in HCV: second-generation protease inhibitors.
    Clark VC; Peter JA; Nelson DR
    Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment failure with new hepatitis C drugs.
    Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon stimulated genes and hepatitis C virus infection.
    Asselah T
    J Interferon Cytokine Res; 2012 Dec; 32(12):557-62. PubMed ID: 23151203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T; Marcellin P
    Liver Int; 2012 Feb; 32 Suppl 1():88-102. PubMed ID: 22212578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
    Hézode C
    Liver Int; 2012 Feb; 32 Suppl 1():32-8. PubMed ID: 22212569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boceprevir for chronic HCV genotype 1 infection.
    Limaye AR; Draganov PV; Cabrera R
    N Engl J Med; 2011 Jul; 365(2):176; author reply 177-8. PubMed ID: 21751914
    [No Abstract]   [Full Text] [Related]  

  • 31. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus-human immunodeficiency virus coinfection.
    Sulkowski MS
    Liver Int; 2012 Feb; 32 Suppl 1():129-34. PubMed ID: 22212583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to optimize HCV therapy in genotype 4 patients.
    Esmat G; El Kassas M; Hassany M; Gamil ME; El Raziky M
    Liver Int; 2013 Feb; 33 Suppl 1():41-5. PubMed ID: 23286845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Barritt AS; Fried MW
    Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
    Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future for the treatment of genotype 4 chronic hepatitis C.
    Esmat G; El Raziky M; El Kassas M; Hassany M; Gamil ME
    Liver Int; 2012 Feb; 32 Suppl 1():146-50. PubMed ID: 22212586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.